Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 7, 2007

Diagnostic Test for Melanoma Goal of NYU Medical Center and Rosetta Genomics Partnership

  • Rosetta Genomics will be working with NYU Medical Center to develop a diagnostic test for melanoma. The partners will focus on identifing miRNAs that can be used as prognostic indicators for the overall survival of melanoma patients and the risk that the disease will metastasize to distant sites.

    “We believe that through our work with microRNAs, which have been shown to hold tremendous potential as biomarkers, we will be able to better understand both the origins and the development of the disease,” comments Eva Hernando of the department of pathology at the NYU School of Medicine. “NYU’s extensive experience with melanoma combined with Rosetta Genomics knowledge in microRNAs offers an exciting research opportunity.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »